Edward (Eddy) Han-Burgess was recently invited to attend the Aspen Ideas Festival Spotlight Health as a PhRMA Aspen Scholar. He joined four other emerging leaders from the biopharma industry from AstraZeneca, Eli Lilly and Company, Merck, and Novartis for a series of events on the new era of medicine and as a conference participant. 

Earlier this month, UCB supported Georgia BioEd Institute’s Summer Biotech Immersion Program. The pilot program took place at Paulding County High School from June 4-8. Eight biology and biotechnology teachers from metro Atlanta area high schools attended the laboratory-intensive professional learning experience in Marc Pedersen’s classroom, 2017 Biology Teacher of the Year.

L to R: Eddie Lee, Pharm.D., Robert Suruki, Sc.D., Ali Bozorg, M.D., Pamela Doty Braker, Ph.D., Stephen Yates, Ph.D.

Last week, 55 U.S.-based biopharmaceutical researchers from 20 different companies headed to Capitol Hill to share their stories with members of the U.S. Congress as part of the 2018 Pharmaceutical Research and Manufacturers of America (PhRMA) GoBoldly Fly-In.

Last month, UCB teamed up with Rebuilding Together®Silicon Valley, a non-profit organization committed to repairing homes for older Americans or people living with disabilities who are physically and financially unable to maintain safe living conditions.

We’re excited to be in Boston this week at the kickoff of the 25th 2018 BIO International Convention.

• The U.S. Food and Drug Administration’s (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology
• CIMZIA Phase 3 psoriasis studies demonstrated significant and clinically meaningful improvements in biologic-naïve patients and those previously treated with biologics, with clinical benefit maintained through 48 weeks and the flexibility of two dose regimens that allow for tailored treatment¹

We are pleased to recognize two UCB leaders, Patty Fritz and Stephanie Hunter-Banks, who were recently appointed to leadership positions for Georgia healthcare industry groups: Georgia Bio and Healthcare Businesswomen’s Association (HBA), Atlanta Chapter, respectively. In support of our corporate strategy to create maximum value for patients, UCB is dedicated to encouraging diversity and inclusion. We are proud to celebrate the accomplishments of these two leaders who encourage and inspire the UCB colleagues around them.

Last year, the Secretary of Health and Human Services (HHS) appointed UCB’s Kristi Lengyel, Director of U.S. Patient Advocacy, to the National Institutes of Health (NIH) Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC). 

CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

• BRIVIACT^® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
• Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
• Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,^{1, 2}
• Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.